Publications
Research at the Leibniz Institute for Immunology focuses on the development of pioneering immune-cell therapies targeting cancer, autoimmune diseases, and chronic inflammation. While developments in this field are highly relevant within the medical community, they are also of great interest to the wider general public. The LIT has a comprehensive archive of international articles, publications, lectures, and online resources aimed at a variety of audiences. So, whoever you are, if you do not find what you are looking for, please do not hesitate to contact us.
Givi S, Lohnes BJ, Ebrahimi S, Riedel S, Khokhali S, Khan SA, Keller M, Wolfel C, Echchannaoui H, Bockamp E, Andre MC, Abken H, Theobald M, Hartwig UF. CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma. Int J Mol Sci. 2025 Aug 25. 26doi:10.3390/ijms26178235. PMID: 40943160
Barden M, Holzinger A, Abken H. CAR T cells in solid tumors: resistance mechanisms. Inn Med (Heidelb). 2025 Aug. 66:803–809. doi:10.1007/s00108-025-01943-z. PMID: 40560389
Beumer N, Imbusch CD, Kaufmann T, Schmidleithner L, Gutter K, Stuve P, Marchel H, Weichenhan D, Bahr M, Ruhland B, Marini F, Sanderink L, Ritter U, Simon M, Braband KL, Voss MM, Helbich SS, Mihoc DM, Hotz-Wagenblatt A, Nassabi H, Eigenberger A, Prantl L, Gebhard C, Rehli M, Strieder N et al. DNA hypomethylation traits define human regulatory T cells in cutaneous tissue and identify their blood recirculating counterparts. Nat Immunol. 2025 Aug. 26:1315–1328. doi:10.1038/s41590-025-02210-x. PMID: 40670618
Renner K, Stauffenberg F, Paulus M, Neumayer S, Winter-Kohler F, Buchtler S, Schmalenberger D, Blaas S, Mohr A, Pfeifer M, Malfertheiner MV, Loew T, Sester M, Bals R, Peterhoff D, Schmidt B, Mack M. Hyper-reactivity of CD8(+) T cells and high expression of IL-3 correlates with occurrence and severity of Long-COVID. Clin Immunol. 2025 Aug. 277:110502. doi:10.1016/j.clim.2025.110502. PMID: 40287027
Sax A, May P, Enssle S, Soliman N, Nedelko T, Mandracci G, Stogbauer F, Joachim L, Winter C, Bassermann F, Steiger K, El Khawanky N, Poeck H, Heidegger S. Defects in the necroptosis machinery are a cancer resistance mechanism to checkpoint inhibitor immunotherapy. J Immunother Cancer. 2025 May 8. 13doi:10.1136/jitc-2024-010433. PMID: 40345706
Enssle S, Sax A, May P, El Khawanky N, Soliman N, Perl M, Enssle JC, Krey K, Ruland J, Pichlmair A, Bassermann F, Poeck H, Heidegger S. Gasdermin E links tumor cell-intrinsic nucleic acid signaling to proinflammatory cell death for successful checkpoint inhibitor cancer immunotherapy. Oncoimmunology. 2025 Dec. 14:2504244. doi:10.1080/2162402X.2025.2504244. PMID: 40366863
Barden M, Holzinger A, Abken H. CAR T cells in solid tumors: resistance mechanisms. Inn Med (Heidelb). 2025 Aug. 66:803–809. doi:10.1007/s00108-025-01943-z. PMID: 40560389
Soliman N, Nedelko T, Mandracci G, Enssle S, Grass V, Fischer JC, Bassermann F, Poeck H, Kobold S, El Khawanky N, Heidegger S. Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors. Cancer Res. 2025 Jul 15. 85:2679–2693. doi:10.1158/0008-5472.CAN-24-3425. PMID: 40305099
Kohne M, Shakiba MH, Schmidleithner L, Schulte-Schrepping J, Scholz R, Elmzzahi T, Sommer D, Li Y, Carraro C, De Domenico E, Wissfeld J, Handler K, Hamada D, Frolov A, Cheng X, Baumgart AK, Holsten L, Osei-Sarpong C, Bourry S, Thabet Y, Renken H, Paulusch S, Sadlon T, Buch T, Wunderlich FT et al. Satb1 directs the differentiation of T(H)17 cells through suppression of IL-2 expression. Cell Rep. 2025 Jul 22. 44:115866. doi:10.1016/j.celrep.2025.115866. PMID: 40531625
N RC, Gerlach C. The T cell subsetting challenge. Trends Immunol. 2025 Jul. 46:505-507. doi:10.1016/j.it.2025.05.005. PMID: 40527649